Clinical Trial Search

Primary: Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) — 41; 30; 25 Participants

Primary: Primary Outcome 1: Forced Expiratory Volume (FEV1) at 48-Hours Post-Surgery — 1.2; 0.93 Liters (L) — p=0.0223

Primary: The Number of Patients With a Response (Complete Response and Partial Response) — 8 Participants

Primary: Local Failure Rates by CT Scan — 15 % of participants

Primary: Skin Temperature — 31.18; 31.21; 31.1; 31.93 degrees celsius

Primary: Mean Depth of Necrosis Achieved With the LMIC-adapted CryoPen and the Thermocoagulator Compared to Mean Depth of Necrosis Achieved With CO2-based Cryotherapy — 6.0; 5.6…

Primary: Area Under the Curve (AUC) EORTC CIPN20 Sensory Neuropathy Subscale Adjusting for Baseline — -1.4; -4.4 Average(subscale value*assessment) — p=0.26

Primary: Number of Participants Undergoing Image-guided Cryoablation of a Head, Neck, or Spine Tumor With Adverse Events — 3; 0 participants

Primary: Prevention of Peripheral Neuropathy During Taxane Chemotherapy — 7.28 score on a scale

Primary: The Level of Post-endodontic Pain — 1.85; 2.15; 3.65 score on a scale — p=0.986

Primary: Proportion of Patients With Successful Outcomes (<5-point Decrease in FACT-NTX From Baseline) — 0.45; 0.59; 0.52 Proportion of Patients

Primary: Immunologic Response as Measured by ELISPOT Assay and Flow Cytometry — 1; 3; 2 Participants

Primary: Decrease in Pain and Symptoms Caused by Hypertonia in the Upper Arm as Measured by an Improvement of 1 Point or Greater on the Modified Ashworth Scale (MAS) at Day 7…

Primary: Subjective Injection Pain — 7.0; 3.1; 3.0; 1.8 units on a scale

Primary: Number of Participants With Effectiveness and Safety Success — 30; 41 participants

Primary: Safety of Ablation Using the AFreeze Cryoablation System Consisting of the CoolLoop® Ablation Catheter, Its Steerable Sheath and the Cryoconsole Cryo-Caddy Assessed by…

Primary: Local Inbreast Breast Tumor Recurrence (IBTR) Rate — 4.3 Percentage of participants with IBTR

Primary: Change in Severity of Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline to 3 Months — 5.9; 9.1; 1.9; 5.7 units on a scale

Primary: Maximum Inspired Volume — 2250; 1300 mL

Primary: Daily Numeric Pain Score — 7.48; 6.47 score on a scale — p=0.2228

Primary: Average Pain (Mastectomy Subjects Only) — 0.0; 3.0 score on a scale

Primary: Eradication of Barrett's Esophagus — 2 Participants

Primary: rTNSS Responder Rate — 47; 23 Participants

Primary: Success (Reduction in Menstruation to Normal Levels) — 59 Participants — p=.271

Primary: Change in Visual Analogue Scale (VAS) Pain Score — 4.94; 7.50; 4.57; 6.25 scores on a scale

Primary: Number of Participants Evaluated for Adverse Events — 5 Participants

Primary: Length of Hospitalization — 3; 5 Length of Stay (Post-Operative Days)

Primary: Chronic Effectiveness (Through 6 Months) of the Freezor Xtra Catheter for the Treatment of AVNRT Using an Endocardial Approach. — 368; 29 Participants — p=<0.0001

Primary: Depth of Injury — 4.0; 5.2 millimeters

Primary: Number of Participants With Complete Eradication of Esophageal Dysplasia — 51 Participants